Market capitalization | $423.43m |
Enterprise Value | $325.70m |
P/E (TTM) P/E ratio | 4.92 |
EV/FCF (TTM) EV/FCF | 4.56 |
EV/Sales (TTM) EV/Sales | 1.87 |
P/S ratio (TTM) P/S ratio | 2.44 |
P/B ratio (TTM) P/B ratio | 2.50 |
Dividend yield | 0.00% |
Last dividend (FY23) | $0.42 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast SIGA Technologies Inc:
1 Analyst has issued a forecast SIGA Technologies Inc:
Sep '24 |
+/-
%
|
||
Revenue | 174 174 |
399%
399%
|
|
Gross Profit | 142 142 |
359%
359%
|
|
EBITDA | 105 105 |
1,227%
1,227%
|
EBIT (Operating Income) EBIT | 105 105 |
1,161%
1,161%
|
Net Profit | 86 86 |
1,814%
1,814%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
SIGA Technologies, Inc. engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.
Head office | United States |
CEO | Diem Nguyen |
Employees | 45 |
Founded | 1995 |
Website | www.siga.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.